Rs5065

rs5065, also known as T2238C, is a SNP in the atrial natriuretic precursor A NPPA gene.

A large study has been conducted in which 42,418 hypertensive participants 55 or older were followed for several years while on one of four medications: a diuretic, a calcium antagonist, an angiotensin-converting enzyme inhibitor, or an alpha-blocker. The primary endpoint was either fatal heart disease or a heart attack.

The blood pressure after six months of rs5065(G;G) patients (note: genotype is in dbSNP orientation, not as published) was lower if the patients were treated with diuretics compared to other medications, with smaller variation seen for (A;A) genotypes. The authors noted that none of the findings retained statistical significance after correction for multiple comparisons, but since the trend held in five of seven outcomes, they felt the results were nonetheless worth reporting.

In summary, rs5065(G) allele carriers were better off (i.e. experienced more favorable cardiovascular disease outcomes) if treated with the diuretic (in this case, chlorthalidone), whereas rs5065(A;A) carriers were better off if treated with the calcium channel blocker (in this case, amlodipine).